Literature DB >> 15663342

Role of imiquimod in skin cancer treatment.

Mirjana Urosevic1, Reinhard Dummer.   

Abstract

Cancer of the skin is by far the most common form of all cancers. Given the increasing incidence of skin cancer worldwide, it seems feasible to reconsider the treatment options available for dealing with this growing problem. Despite the lower costs associated with classical methods such as surgery and radiotherapy, immune response modifiers such as imiquimod appear to be good candidates for the future given their good cosmetic effects, the possibility of treating large areas, and the simpleness of patient-applied treatment with a cream formulation. This article reviews current literature on the use of imiquimod in the treatment of nonmelanoma and melanoma skin cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15663342     DOI: 10.2165/00128071-200405060-00010

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  8 in total

1.  Frequent calcium oscillations lead to NFAT activation in human immature dendritic cells.

Authors:  Mirko Vukcevic; Francesco Zorzato; Giulio Spagnoli; Susan Treves
Journal:  J Biol Chem       Date:  2010-03-26       Impact factor: 5.157

Review 2.  Polymeric nanoparticles-based topical delivery systems for the treatment of dermatological diseases.

Authors:  Zheng Zhang; Pei-Chin Tsai; Tannaz Ramezanli; Bozena B Michniak-Kohn
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2013-02-05

3.  Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice.

Authors:  Wen-Wei Zhang; Greg Matlashewski
Journal:  Infect Immun       Date:  2008-05-12       Impact factor: 3.441

4.  A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.

Authors:  Lydia Bellmann; Giuseppe Cappellano; Johanna F Schachtl-Riess; Anastasia Prokopi; Athanasios Seretis; Daniela Ortner; Christoph H Tripp; Constance E Brinckerhoff; David W Mullins; Patrizia Stoitzner
Journal:  Int J Cancer       Date:  2019-12-04       Impact factor: 7.396

5.  pH-Responsive Nanostructures Based on Surface Active Fatty Acid-Protic Ionic Liquids for Imiquimod Delivery in Skin Cancer Topical Therapy.

Authors:  Silvia Tampucci; Lorenzo Guazzelli; Susi Burgalassi; Sara Carpi; Patrizia Chetoni; Andrea Mezzetta; Paola Nieri; Beatrice Polini; Christian Silvio Pomelli; Eleonora Terreni; Daniela Monti
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

Review 6.  Parapsoriasis-A Diagnosis with an Identity Crisis: A Narrative Review.

Authors:  Manasmon Chairatchaneeboon; Kanchalit Thanomkitti; Ellen J Kim
Journal:  Dermatol Ther (Heidelb)       Date:  2022-04-15

7.  Immune microenvironment in tumor progression: characteristics and challenges for therapy.

Authors:  Valerie Chew; Han Chong Toh; Jean-Pierre Abastado
Journal:  J Oncol       Date:  2012-08-08       Impact factor: 4.375

8.  RNASEL and MIR146A SNP-SNP interaction as a susceptibility factor for non-melanoma skin cancer.

Authors:  Shohreh F Farzan; Margaret R Karagas; Brock C Christensen; Zhongze Li; Jacquelyn K Kuriger; Heather H Nelson
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.